Aulos Bioscience is a clinical-stage, immuno-oncology company developing imneskibart (AU-007), an immune-activating antibody therapeutic designed by leveraging an AI platform. Imneskibart is being evaluated in a Phase 1/2 clinical study, with Phase 2 data demonstrating sustained and significant anti-tumor activity in patients with melanoma that progressed on prior doublet checkpoint inhibitor (CPI) therapy and early signals of objective responses in patients with non-small cell lung cancer (NSCLC) whose tumors progressed on prior CPI therapy, with or without chemotherapy. Data also reinforce that a persistent reduction in Tregs coupled with a higher CD8/Treg ratio is associated with longer overall survival, progression-free survival and time on treatment for patients.
If you’re interested in investing in Aulos, please contact info@aulosbio.com.
AULOS CO-FOUNDERS
Aulos was co-founded by Biolojic Design and ATP, with $60 million in Series A funding from ATP. The company is led by pioneers in the fields of artificial intelligence, antibody development and cancer immunotherapies.
LATEST NEWS
AULOS FEATURED IN THE NEWS
Drug Discovery World
One to watch: How Aulos is advancing immunotherapy cancer treatments
November 12, 2025
CEO Aron Knickerbocker shares how Aulos is rethinking immunotherapy with imneskibart, an immune-activating antibody designed to drive durable tumor reductions in melanoma, NSCLC and other tumor types.
Empowered Patient Podcast
Harnessing AI to Design Antibodies and Further Unlock the Immune System to Target Cancer Cells with Aron Knickerbocker Aulos Bioscience
August 6, 2025
Host Karen Jagoda and CEO Aron Knickerbocker dive into why Aulos is a company to watch and its “moon landing” with an AI-assisted antibody that drives down Tregs – a first in the IL-2 class.
VIDEOS ABOUT OUR TECHNOLOGY
Understanding the human immune system and combating diseases like cancer can be complex. In the fight against cancer, what if artificial intelligence could design a drug that helps solve one of the biggest challenges in immunotherapy – safely harnessing the power of IL-2?
The currently approved form of recombinant human IL-2 requires high doses that can be toxic and lead to cytokine storms as well as increased risk of pulmonary edema and blood vessel leakage. Newer generation IL-2 mimetics that are not yet approved can also create a negative feedback loop by triggering the secretion of more IL-2, which can lead to the expansion of regulatory T cells that suppress the very immune response the cancer treatment was meant to activate. Addressing these complexities requires IL-2 regulation, precision and innovation. That’s where Aulos comes in.